Trial Profile
A Mass Balance Study to Investigate the Absorption, Metabolism, Excretion of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371- Microtracer Dose in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Delpazolid (Primary)
- Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Tuberculosis; Vancomycin-resistant enterococcal infections
- Focus Pharmacokinetics
- Sponsors LegoChem Biosciences
- 10 Mar 2021 Status changed from active, no longer recruiting to completed.
- 29 Jul 2020 Planned End Date changed from 1 Apr 2022 to 1 Oct 2020.
- 29 Jul 2020 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2020.